High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

ABSTRACT:

Objectives

HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the prevalence of integrase resistance mutations, including L74I, in West Africa.

Methods

We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists.

Results

Of 115 individuals,

SUBMITTER: El Bouzidi K 

PROVIDER: S-EPMC7225870 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature